Introduction
Antibiotics are used extensively in both humans and in animals. In Australia, the amount of antibiotics used in animals is greater than in humans'. The three main uses of antibiotics in livestock are for growth promotion, prophylaxis and to treat sick animals 2.
Antibiotic use in animals, however, is also a potential problem for human medicine as antibiotic resistant bacteria can pass through the food chain to people',2,! In the past, the main concerns we have had with food borne bacteria were those that produced frequent and/or severe disease in people, for example Salmonella sp. and Campylobacter sp. which cause gastroenteritis. However, more recently, there have been growing concerns about bacteria that cause disease in people less frequently, but are transferred more frequently via the food chain, i.e. Esckerickia coli and Enterococci. These latter bacteria, as well as Salmonella sp. and Campylobacter sp. frequently carry gene encoding for antibiotic resistan~e'.~,'.
Vancomycin and ci profloxacin resistance
Vancomycin and ciprofloxacin resistance are linked to antibiotic use in animals.
Vancomycin resistance
In Europe, there is strong evidence' that VRE develop in animals that have been fed an antibiotic called avoparcin, a glycopeptide or vancomycin-like antibiotic. These strains of VRE may then remain on the carcasses of animals after slaughter and remain on foods that are sold at the retail level.
One study in the Netherlands showed that over 70 per cent of chickens tested at the retail level had VRE present3. In studies of the European population, it has been found that between 2-17 per cent have these multi antibiotic resistant bacteria present in their bowel 3.
The conclusion from all of this data is that VRE is widespread in Europe and that avoparcin use in animals is the major reason why VRE has spread in the food chain. Vancomycin resistance concerns us in human medicine because it is a 'last-line' antibiotic. Therefore, if resistance develops to this antibiotic, this will mean that we usually have no alternative antibiotics available to treat serious infections. This occurs now for some people with VRE infections.
Another larger concern is whether these vancomycin resistance genes may eventually spread from VRE to much more common and aggressive bacteria such as multi resistant strains of Staphylococcus aureus (MRSA). Experimentally, this has been shown to occur. If this ever happened in our hospitals, we would have the situation where one of the most aggressive bacteria causing infections in people may be untreatable with antibiotics3.
In Australia, we have much less data on the spread of VRE through the food chain. We do, however, know that VRE in Australia is widespread and has been found in small community hospitals as well as larger ones',3. VRE has also been isolated in food production animals in Australia','. The most logical explanation for this spread in Australia, as in Europe, is that VRE is spread through the food chain.
Wherever antibiotics are used, we know that one of the consequences of their use is that resistance can develop. The amount of resistance that eventuates is believed to be related to the total amount of antibiotic used. In 1992, over 120,000 kgs of avoparcin (10 per cent active ingredient by weight) was used in animals in Australia predominantly as a growth promoter, while only 68 kg of vancomycin was used in
There is also a debate as to whether antibiotics used as growth promoters really lead to any significant economic benefits. i.e. weight gains and improved feed efficiency. In some recent studies, no benefits were seen2. At best, and with good farming methods, this weight gain is only a few per cent. Economically, this translates to no more than 3 cents per chicken or a few cents per kg in pork',2.
The large amount of avoparcin used, which is in the class of antibiotics that are 'last line 'or 'critical' to humans, appears to be a waste of a precious resource'. Any small economic benefits that may flow to the agricultural sector appear to be more than outweighed by the major risks to human health (and increased hospital costs) by the potential widespread circulation of these multi resistant bacteria through the food chain.
Ciprofloxacin resistance
In the USA and Europe, a fluoroquinolone similar to ciprofloxacin (enrofloxacin) has been associated with the spread of ciprofloxacin resistant Salmonella sp., Campylobacter sp. as well as resistant E. coli to humans through the food chain'-6. This has resulted in Salmonella Limiting the amount of antibiotic resistance What can be done to limit the amount of antibiotic resistance that occurs? There will always be new antibiotics and there will always be controversy about the economic and medical costs of their use compared to their benefits, both in humans and in animals. It is important that we have some antibiotics available for use in treating sick animals. However, we need to limit the ways that antibiotics are used in food production animals.
In particular, antibiotics should not be used for growth promotion and they should be used only sparingly for prophylaxis. Of particular importance is that antibiotics that are 'critical' or 'last line' for human use, should not be used in food production animals at all. These 'critical' antibiotics make up only a small percentage of the total amount of antibiotics that are used in humans. If these were reserved for human use alone, this is unlikely to compromise animal welfare.
The basic principles we need to follow in order to maintain or facilitate this approach not only now, but also in the future, are:
Antibiotics that are 'critical' or 'last-line' for serious human infections should not be used in food production animals or agriculture.
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The use of antibiotics for prophylactic purposes in animals should be kept to a minimum. The overall current usage for this purpose should be significantly reduced. The use of methods, not antibiotics, to prevent infections should be expanded and developed.
Antibiotics should not be used as growth promoters.
Conclusion
Antibiotics are a precious but non-renewable resource. 
